Clinical Report: Glaucoma: A New Prescribing Mindset

Overview

This report discusses the impact of benzalkonium chloride (BAK)-containing glaucoma drops on dry eye disease (DED) and patient adherence. It advocates for a shift in treatment strategy, suggesting selective laser trabeculoplasty as a first-line option for certain patients to mitigate the adverse effects of these drops.

Background

The management of glaucoma is critical due to its potential to cause irreversible vision loss. BAK-containing glaucoma medications, while effective, can exacerbate dry eye disease, leading to increased nonadherence among patients. Understanding the relationship between glaucoma treatments and ocular surface health is essential for optimizing patient outcomes.

Data Highlights

No numerical data presented in the article.

Key Findings

• Nonadherence to glaucoma therapy is nearly three times higher in patients using preserved drops compared to preservative-free options.
• Each additional BAK-containing drop doubles the odds of corneal or conjunctival staining, indicating chronic inflammation and toxicity.
• Long-term exposure to BAK can lead to meibomian gland dysfunction and blockage.
• Signs of discomfort from BAK-containing drops may include punctate keratitis, hyperemia, and fluctuating vision.
• Switching to selective laser trabeculoplasty may be beneficial for patients with existing DED rather than continuing with drops.

Clinical Implications

Healthcare professionals should consider the ocular surface health of glaucoma patients when prescribing medications. A proactive approach, including the use of selective laser trabeculoplasty, may enhance patient adherence and overall treatment success.

Conclusion

Adopting a new mindset in glaucoma management that prioritizes ocular surface health can lead to better patient outcomes. This approach emphasizes the importance of individualized treatment strategies.

References

1. Wolfram C, Stahlberg E, Pfeiffer N, J Ocul Pharmacol Ther, 2019 -- Patient-reported nonadherence with glaucoma therapy
2. Leung EW, Medeiros FA, Weinreb RN, J Glaucoma, 2008 -- Prevalence of ocular surface disease in glaucoma patients
3. Arita R, Itoh K, Maeda S, et al., Cornea, 2012 -- Comparison of the long-term effects of various topical anti-glaucoma medications on meibomian glands
4. Glaucoma Physician — Individualizing Glaucoma Medical Management
5. Ophthalmology Management — Guest Editorial
6. Optometric Management — CLINICAL: Contact Lenses Recommendations
7. Optometric Management — Add Glaucoma Management to Your Practice
8. Individualizing Glaucoma Medical Management
9. Be an active glaucoma provider
10. Contact Lenses Recommendations
11. European Glaucoma Society – Terminology and guidelines for glaucoma, 6th Edition
12. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT)
13. The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells - PubMed